Compound-42 alleviates acute kidney injury by targeting RIPK3-mediated necroptosis,British Journal of Pharmacology

当前位置： X-MOL 学术 › Br. J. Pharmacol. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

Compound-42 alleviates acute kidney injury by targeting RIPK3-mediated necroptosis
British Journal of Pharmacology ( IF 6.8 ) Pub Date : 2023-05-30 , DOI: 10.1111/bph.16152
Xiao-Yan He ₁ , Fang Wang _{1,

2} , Xiao-Guo Suo ₁ , Ming-Zhen Gu ₁ , Jia-Nan Wang ₁ , Chuan-Hui Xu ₁ , Yu-Hang Dong ₁ , Yuan He ₁ , Yao Zhang ₁ , Ming-Lu Ji ₁ , Ying Chen ₁ , Meng-Meng Zhang ₁ , Yin-Guang Fan ₃ , Jia-Gen Wen ₁ , Juan Jin ₄ , Jie Wang ₁ , Jun Li ₁ , Chun-Lin Zhuang ₅ , Ming-Ming Liu ₁ , Xiao-Ming Meng ₁

Affiliation

Necroptosis plays an essential role in acute kidney injury and is mediated by receptor-interacting protein kinase 1 (RIPK1), receptor-interacting protein kinase 3 (RIPK3), and mixed lineage kinase domain-like pseudokinase (MLKL). A novel RIPK3 inhibitor, compound 42 (Cpd-42) alleviates the systemic inflammatory response. The current study was designed to investigate whether Cpd-42 exhibits protective effects on acute kidney injury and reveal the underlying mechanisms.

中文翻译：

化合物 42 通过靶向 RIPK3 介导的坏死性凋亡减轻急性肾损伤

坏死性凋亡在急性肾损伤中发挥重要作用，由受体相互作用蛋白激酶 1 (RIPK1)、受体相互作用蛋白激酶 3 (RIPK3) 和混合谱系激酶结构域样假激酶 (MLKL) 介导。化合物 42 (Cpd-42) 是一种新型 RIPK3 抑制剂，可减轻全身炎症反应。本研究旨在探讨 Cpd-42 是否对急性肾损伤具有保护作用并揭示其潜在机制。

更新日期：2023-05-30

点击分享查看原文

点击收藏

阅读更多本刊新发论文本刊介绍/投稿指南